Catalyst Biosciences, Inc. (CBIO) Analysts See $-1.79 EPS

February 15, 2018 - By Henry Gaston

 Catalyst Biosciences, Inc. (CBIO) Analysts See $ 1.79 EPS

Analysts expect Catalyst Biosciences, Inc. (NASDAQ:CBIO) to report $-1.79 EPS on March, 14.They anticipate $2.89 EPS change or 61.75 % from last quarter’s $-4.68 EPS. After having $-1.34 EPS previously, Catalyst Biosciences, Inc.’s analysts see 33.58 % EPS growth. The stock decreased 4.05% or $1.37 during the last trading session, reaching $32.45. About 332,326 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has declined 80.67% since February 15, 2017 and is downtrending. It has underperformed by 97.37% the S&P500.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $317.99 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

More important recent Catalyst Biosciences, Inc. (NASDAQ:CBIO) news were published by: which released: “Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product” on February 09, 2018, also published article titled: “Catalyst Biosciences: The Next Acquisition Target?”, published: “Catalyst Biosciences makes second large securities offering” on February 14, 2018. More interesting news about Catalyst Biosciences, Inc. (NASDAQ:CBIO) was released by: and their article: “Catalyst Biosciences Announces Closing of Public Offering of Common Stock” with publication date: February 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.